Expert Interview
Discussing the results from the Phase 2 ASPEN-06 Clinical Trial of ALX Oncology’s investigational CD47-blocking therapeutic, evorpacept, for gastric cancer
Ticker(s): ALXOInstitution: Duke University
- Instructor of Medical Oncology at Duke who treats gastrointestinal cancers and conducts research on tumor immunology and immunotherapy, particularly for melanoma and gastrointestinal malignancies.
- Laboratory and translational research is focused on tumor immune evasion and immunotherapy resistances, and the development of biomarkers with a specific interest in dendritic cell tolerance.
- Research and clinical goal of finding new immunotherapeutic options for patients with supportive biomarkers to identify patients.
Roughly how many patients with gastric cancer do you currently manage?
Added By: ben_adminCould you talk a little bit about your professional background, and
some details about your clinical practice?
What are your thoughts on the approach of evorpacept? And is this
differentiated at all in this space, in your view?
If you had to rate your level of excitement about evorpacept on a
one to 10 scale, how would you rate that and why?
How do you interpret the difference in efficacy seen from the interim analysis?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
